Trials / Not Yet Recruiting
Not Yet RecruitingNCT07517653
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
A Multicenter, Phase II Clinical Trial of Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma (The ASPRIE-MM Study)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 | Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China |
| DRUG | Famitinib | Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-11-30
- Completion
- 2028-12-30
- First posted
- 2026-04-08
- Last updated
- 2026-04-08
Source: ClinicalTrials.gov record NCT07517653. Inclusion in this directory is not an endorsement.